Oxford, UK – 02 February 2010. OGT, the pioneer of microarray based technologies, has introduced three new CytoSure® ISCA aCGH arrays to meet all resolution, multiplexing and budget requirements. Designed in collaboration with the International Standard Cytogenomic Array (ISCA) Consortium, the 8 x 60k, 4 x 180k and 4 x 44k CytoSure ISCA formats, provide powerful arrays focusing on disease and syndrome-associated genome regions, in addition to offering whole genome coverage. Using a proprietary 60-mer probe design and multiple rounds of optimisation, the CytoSure ISCA aCGH arrays ensure exceptional reliability and confident detection of genetic aberrations with high signal-to-noise ratios. These features have ensured that the CytoSure ISCA arrays are already used at a number of key facilities, including the Wessex Regional Genetics Laboratory, Salisbury UK where they were evaluated as part of an ongoing multi-platform aCGH comparison being carried out by the National Genetics Reference Laboratory (Wessex).
Each CytoSure array is accompanied with the user-centric CytoSure Interpret analysis software. This powerful and easy-to-use tool ensures effortless translation of data into meaningful results. Intuitive features include the “Accelerate” workflow, for customisable automation of routine data analysis, and full integration with existing data and publicly available cytogenetics databases including the Database of Genomic Variants (DGV, Canada) and DECIPHER (Sanger Institute, UK). “OGT has a strong and ongoing commitment to providing cytogeneticists with exceptional tools for accurate and reliable aberration detection” stated James Clough, OGT’s Vice President Clinical and Genomic Solutions, “The development of our CytoSure ISCA arrays, in combination with our advanced CytoSure Interpret analysis software, is a clear example of this. We are delighted by the level of interest our CytoSure ISCA arrays are generating within the ISCA consortium around the world”.
In addition to CytoSure ISCA arrays and Interpret software, the CytoSure aCGH product line includes a range of high quality arrays covering single disorders through to entire syndrome spreads, as well as SciGene automation instrumentation (now distributed in Europe by OGT). As a result, OGT’s comprehensive products and services are the ideal solution for running oligo aCGH in the laboratory.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.Read
CytoSure™ NGS – Combining the benefits of microarrays and NGS in a single assay.Read
Reinforcing collaboration toward the realisation of genomic medicine in the area of ophthalmic disorders.Read